Get the Stockscreener App
21.90
0.27%
-0.12
Cidara Therapeutics Inc stock is traded at $21.90, with a volume of 97,770.
It is down -0.27% in the last 24 hours and up +5.15% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$22.02
Open:
$21.99
24h Volume:
97,770
Relative Volume:
0.64
Market Cap:
$282.88M
Revenue:
$56.54M
Net Income/Loss:
$-30.70M
P/E Ratio:
-56.15
EPS:
-0.39
Net Cash Flow:
$-31.05M
1W Performance:
-9.56%
1M Performance:
+5.15%
6M Performance:
+8.66%
1Y Performance:
+76.81%
1-Day Range:
$21.57
$22.34
1-Week Range:
$21.57
$24.91
52-Week Range:
$10.14
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
21.81 | 333.32M | 56.54M | -30.70M | -31.05M | -0.39 |
|
ONC
Beone Medicines Ltd Adr
|
245.47 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.48 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.24 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.24 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Northern Trust Corp Has $913,000 Stock Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals - Value The Markets
Cidara Therapeutics (NASDAQ:CDTX) Given “Market Outperform” Rating at JMP Securities - Defense World
JMP Securities Reiterates Market Outperform Rating for Cidara Therapeutics (CDTX) | CDTX Stock News - GuruFocus
Cidara stock target holds at $47 by JMP on trial confidence - Investing.com Canada
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World
(CDTX) On The My Stocks Page - news.stocktradersdaily.com
Cidara Therapeutics: All Stars Aligning In Favor Of CD388 (NASDAQ:CDTX) - Seeking Alpha
Royal Bank of Canada Increases Cidara Therapeutics (NASDAQ:CDTX) Price Target to $35.00 - Defense World
Cidara Therapeutics’ (CDTX) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from Needham & Company LLC - Defense World
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RB - GuruFocus
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RBC Capital | CDTX Stock News - GuruFocus
RBC Capital Ups Price Target for Cidara Therapeutics (CDTX) Amid Optimism | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX): Analyst Reiterates Buy Rating | CDTX Stock News - GuruFocus
RBC Raises Price Target on Cidara Therapeutics to $35 From $31, Keeps Outperform, Speculative Risk - marketscreener.com
Transcript : Cidara Therapeutics, Inc.Special Call - marketscreener.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis - Barchart.com
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
CDTX Stock Price and Chart — NASDAQ:CDTX - TradingView
When (CDTX) Moves Investors should Listen - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Target Price Raised by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenh - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim - TipRanks
Cidara Therapeutics to Host Virtual R&D Day to Discuss - GlobeNewswire
Revolutionary Once-Per-Year Universal Flu Prevention: Cidara Unveils Phase 2b Trial Updates at R&D Day - Stock Titan
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call - MSN
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst Says - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Guggenheim Raises Price Target for Cidara Therapeutics (CDTX) to $35.00 | CDTX Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Caribou Biosciences (CRBU) and Cidara Therapeutics (CDTX) - The Globe and Mail
StockNews.com Upgrades Cidara Therapeutics (NASDAQ:CDTX) to Sell - Defense World
Cidara Therapeutics (CDTX) Target Price Raised by JMP Securities - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised by JMP Securities | CDTX Stock News - GuruFocus
RBC Cuts Price Target on Cidara Therapeutics to $31 From $34, Keeps Outperform, Speculative Risk - marketscreener.com
Cidara Therapeutics (CDTX) Target Price Raised to $35 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Sees Price Target Increase by Citizens JMP | CDTX Stock News - GuruFocus
Cidara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in ... - Yahoo Finance
Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in Influenza Prevention Amid Financial Challenges - GuruFocus
Cidara Therapeutics Reports Q1 2025 Financial Results - TipRanks
CDTX Targets Key Data Release for Influenza Treatment by Mid-202 - GuruFocus
Cidara Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CDTX Targets Key Data Release for Influenza Treatment by Mid-2025 | CDTX Stock News - GuruFocus
Cidara Therapeutics reports Q1 EPS ($1.66) vs. ($2.28) last year - TipRanks
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | CDTX Stock News - GuruFocus
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cidara Therapeutics Inc Stock (CDTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
| Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
| Stein Jeffrey | President & CEO |
Jun 07 '24 |
Buy |
13.21 |
8,000 |
105,680 |
24,580 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):